{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:05:07Z","timestamp":1789362307389,"version":"build-2803163510"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006701","name":"Umm Al-Qura University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ibrutinib is widely used in B-cell malignancies, yet real-world safety data remain heterogeneous, particularly in underrepresented regional populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize the adverse-event profile and severity and explore factors associated with Grade 3\u20135 toxicity and permanent treatment discontinuation among patients receiving ibrutinib in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted at King Abdullah Medical City, Makkah, Saudi Arabia, with follow-up through December 2025. Adult patients with B-cell malignancies who received ibrutinib and had sufficient clinical documentation for safety-outcome ascertainment were included. The primary endpoint was the occurrence of at least one Grade 3\u20135 adverse event according to CTCAE v5.0. Secondary outcomes included dose modifications, permanent treatment discontinuation, factors associated with toxicity, and temporal adverse-event patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 57 patients, all 57 (100%) experienced at least one adverse event and 41 (71.9%) experienced at least one Grade 3\u20135 adverse event. Neutropenia and hypertension were the most frequent severe toxicities. Dose modification occurred in 47 patients (82.5%), and permanent discontinuation occurred in 17 (29.8%). In reduced Firth penalized-likelihood models adjusted for starting-dose category, pre-existing ischemic heart disease was associated with permanent discontinuation (aOR 6.25, 95% profile-likelihood CI 1.29\u201339.19;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023), while creatinine clearance &amp;lt;60\u2005mL\/min was associated with Grade 3\u20135 toxicity (aOR 5.53, 95% profile-likelihood CI 1.26\u201338.46;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022). A patient-level omnibus permutation test indicated a difference in adverse-event cluster distributions between the early (\u226490 days) and late (&amp;gt;90 days) periods (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), although an equal-window sensitivity analysis comparing days 0\u201390 with days 91\u2013180 was not significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.240).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ibrutinib was associated with substantial toxicity and frequent treatment modification in routine clinical practice. Pre-existing ischemic heart disease and impaired renal function emerged as exploratory markers of treatment vulnerability. The temporal findings support continued surveillance throughout therapy but do not establish a phase-specific monitoring strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1897420","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:38:36Z","timestamp":1789360716000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world toxicity and discontinuation risk in ibrutinib therapy: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Wid M.","family":"Alyamani","sequence":"first","affiliation":[{"name":"Pharmaceutical Care, King Abdullah Medical City","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attiah","family":"Khobrani","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care, King Abdullah Medical City","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawaz O.","family":"Alenazy","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University","place":["Sakaka, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya A.","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, King Abdulaziz University","place":["Rabigh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maan H.","family":"Harbi","sequence":"additional","affiliation":[{"name":"Pharmacology and Toxicology Department, College of Pharmacy, Umm Al-Qura University","place":["Makkah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s44228-022-00015-5","article-title":"FIRE study: real-world effectiveness and safety of ibrutinib in clinical practice in patients with CLL and MCL","volume":"4","author":"Dartigeas","year":"2022","journal-title":"Clin Hematol Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/medicina59020324","article-title":"Real-world clinical outcomes and adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib: a single-center retrospective study","volume":"59","author":"Moldovianu","year":"2023","journal-title":"Medicina"},{"key":"B10","year":""},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"B12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/ANNALS-24-01926","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2024 clinical practice guideline","volume":"178","author":"Madero","year":"2025","journal-title":"Ann Intern Med"},{"key":"B13","year":""},{"key":"B14","first-page":"i","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","volume":"894","year":"2000","journal-title":"World Health Organ Tech Rep Ser"},{"key":"B15","year":""},{"key":"B16","doi-asserted-by":"publisher","first-page":"1624761","DOI":"10.3389\/fonc.2025.1624761","article-title":"Real-world cardiovascular risks of ibrutinib in chronic lymphocytic leukemia: a retrospective study","volume":"15","author":"Ivanovic","year":"2025","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"oyae229","DOI":"10.1093\/oncolo\/oyae229","article-title":"Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy","volume":"30","author":"Fernandez Turizo","year":"2025","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40959-021-00125-8","article-title":"Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with ibrutinib","volume":"7","author":"Avalon","year":"2021","journal-title":"Cardiooncology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11912-021-01102-1","article-title":"Bruton\u2019s tyrosine kinase inhibitors and cardiotoxicity: more than just atrial fibrillation","volume":"23","author":"Sestier","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1002\/cam4.2998","article-title":"The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice","volume":"9","author":"Parikh","year":"2020","journal-title":"Cancer Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1897420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:38:42Z","timestamp":1789360722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1897420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":21,"alternative-id":["10.3389\/fmed.2026.1897420"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1897420","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1897420"}}